In the honest version of GLP-1 tablets vs injections, the tablets change your daily routine far more than they change the medicine. All four UK options — the Mounjaro and Wegovy weekly injections, and the two licensed pills, the Wegovy pill and Foundayo — switch on the same appetite pathway and produce the same broad family of side effects. What genuinely differs is how often you take a dose and under what rules, how many months it takes to climb to a maintenance dose, and what each one's own trial measured. On average weight loss, the two injections sit above the two tablets in their respective trials — but those trials were separate and measured different people over different lengths of time, so they cannot be read as a league table — the right option for a particular person is a prescriber's judgement.
Until 2026 there was no needle-free option licensed for weight loss in the UK. Two arrived within ten weeks of each other: the Wegovy pill (oral semaglutide), approved by the MHRA on 11 June 2026, and Foundayo (orforglipron), authorised on 10 August 2026.
Three different asks, not two
It is tempting to frame this as "needle or no needle", but there are really three routines here, because the two tablets are nothing like each other in practice.
A weekly injection: Mounjaro and Wegovy
Both are given once a week under the skin using a pre-filled pen. Mounjaro's KwikPen goes into the tummy or thigh — or the back of the upper arm if someone else gives it — at any time of day, with or without food, on the same day each week, rotating the site. Wegovy is the same idea: a self-given weekly injection into the stomach, thigh or upper arm on the same day each week. There is nothing to remember in between; the trade-off is that you have to be comfortable injecting yourself.
A daily tablet with a strict routine: the Wegovy pill
Oral semaglutide is the same active ingredient as the Wegovy injection, but getting a peptide through the stomach intact is difficult, so each tablet includes an absorption enhancer called SNAC. That is why the instructions are so specific. The tablet is swallowed whole with a small sip of plain water — no more than about 120 ml — first thing in the morning on an empty stomach, after an overnight fast of at least 8 hours. You then wait at least 30 minutes before eating, drinking anything else, or taking any other tablets.
Read that again if your day starts with tea, or if you take another tablet first thing. It is a daily commitment, and not a routine that bends easily around shift work or early travel.
A daily tablet with no rules: Foundayo
Foundayo is a different kind of molecule. Orforglipron acts on the same GLP-1 receptor as semaglutide and tirzepatide, but it is a small-molecule drug rather than a peptide, so it is absorbed like an ordinary tablet whatever you have eaten. One tablet a day, any time of day, with or without food, no water limit, no waiting before breakfast. Swallow it whole — do not break, crush or chew it — and keep it in the original blister, because it is light-sensitive. No fridge needed.
How long until you reach the maintenance dose
Every one of these medicines is started low and raised slowly to reduce nausea, so none of them works at full strength from day one. The step-up schedules differ more than people expect.
- Wegovy injection: 0.25 mg weekly for 4 weeks, then 0.5, 1 and 1.7 mg for about 4 weeks each, reaching the usual 2.4 mg maintenance dose from around week 17 — roughly 16 weeks in total. Since January 2026 the MHRA has also approved a higher 7.2 mg weekly dose for obesity only (BMI 30+).
- Mounjaro: 2.5 mg weekly for 4 weeks as a starter dose, not a treatment dose, then 5 mg — the lowest dose you might stay on. Going further means 2.5 mg steps to 7.5, 10 and 12.5, with at least 4 weeks at each, up to a maximum of 15 mg. The maintenance dose (5, 10 or 15 mg) is tailored to you.
- Wegovy pill: 1.5 mg once daily, then 4 mg, then 9 mg, then the full 25 mg maintenance dose, with at least a month at each level — about three months to reach 25 mg.
- Foundayo: 0.8 mg daily for the first month as a starter, then 2.5 mg, then 5.5 mg, which is the first dose you may stay on. Optional steps to 9, 14.5 and 17.2 mg follow depending on response and side effects, at least 30 days apart, so the earliest anyone reaches the maximum 17.2 mg is month 6.
Appetite tends to change long before the maintenance dose arrives. On Mounjaro, reduced appetite is often noticed within the first days to two weeks, with measurable weight loss usually beginning around weeks 4–8. On Wegovy and the Wegovy pill, appetite reduction often begins in the first few weeks. Foundayo's appetite effects start with the first tablets, as the drug reaches a steady level within about a week. In every case the weight loss itself builds over months.
What the trials showed
These are four separate trials with different participants, doses and durations — not a head-to-head — so treat the figures as four separate pictures rather than a ranking.
- Mounjaro (SURMOUNT-1), adults with obesity or overweight without type 2 diabetes, 72 weeks: mean loss 16.0% at 5 mg, 21.4% at 10 mg and 22.5% at 15 mg, versus 2.4% on placebo. About 90% of people on 15 mg lost at least 10% of their body weight.
- Wegovy injection (STEP 1), 68 weeks at 2.4 mg alongside lifestyle changes: about 15% of body weight on average (mean −14.9%), versus about 2.4% on placebo.
- Wegovy pill (OASIS 4, 2025), 64 weeks at 25 mg: about 13.6% on average versus about 2.2% on placebo in the headline analysis; among people who took it consistently the average was about 16.6%, and around 30% of participants lost at least 20% of their body weight.
- Foundayo (ATTAIN-1), adults with obesity or overweight without diabetes, 72 weeks: mean loss 7.8% at 5.5 mg, 9.3% at 9 mg and 12.4% at 17.2 mg, versus 0.9% on placebo. Counting everyone who started, including those who stopped, the top dose gave 11.2% versus 2.1%. About 60% on 17.2 mg lost at least 10% and 40% at least 15%. The 14.5 mg strength was not a trial arm.
Two things are worth holding onto. The Wegovy pill's gap between its headline figure and the figure for people who took it consistently is a reminder that a tablet only works if the routine is followed. And averages hide enormous individual variation.
Who each tends to suit
The licensed populations largely overlap: broadly, adults with a BMI of 30 or more, or 27–30 with a weight-related condition. Within that, the published descriptions of who each option suits differ in useful ways.
Mounjaro suits adults comfortable with a weekly injection who want the option currently linked to the greatest average weight loss — often people needing substantial loss, or who did not get enough from a GLP-1-only medicine. Wegovy suits adults who want a well-established weekly injectable with the longest UK track record and the most trial and real-world data.
The Wegovy pill suits people who want an effective GLP-1 but would prefer a daily tablet to a weekly injection — and can commit to the strict empty-stomach morning routine. That second half of the sentence is the whole decision. Foundayo suits people who want a daily tablet without that routine; people with type 2 diabetes who also need to lose weight, since it is licensed for both; and people stepping down from Mounjaro or Wegovy injections — in a 52-week trial it kept most of the weight off after switching. For more on who qualifies, see our guide to eligibility for GLP-1 treatment in the UK.
Side effects are much the same family
Going oral does not mean a gentler medicine. Across all four, the common side effects are digestive — nausea, diarrhoea, constipation and vomiting — with headache, indigestion or tiredness also reported depending on the product. The less common but more serious risks overlap, though not identically: pancreatitis (rare, and described as uncommon for Foundayo) and gallstones are listed for all four, and dehydration severe enough to strain the kidneys is listed for Mounjaro, the Wegovy pill and Foundayo. People also taking insulin or a sulfonylurea face a higher risk of low blood sugar. The Wegovy injection's labelling additionally notes NAION, a rare eye condition, and Foundayo's notes a faster pulse or low blood pressure. Our guide to managing GLP-1 side effects goes into more detail.
With Foundayo, oral contraceptives may be less reliable for 30 days after starting and after each dose increase — a barrier method or a switch is advised. It also has interactions to check, including clarithromycin, rifampicin, St John's wort and simvastatin. It is a black-triangle medicine under additional monitoring, so side effects should be reported through the MHRA Yellow Card scheme.
Where UK access stands in September 2026
Both tablets are private-prescription only. The Wegovy pill launched to private providers in early July 2026, and NHS funding would need a separate NICE appraisal. Foundayo launched to UK private prescribers on 24 August 2026; NICE is appraising it for overweight and obesity (ID6516), with guidance provisionally expected on 18 November 2026.
The injections are further along. Wegovy is MHRA-approved for weight management, but on the NHS in England it is available only through specialist weight-management services under NICE TA875, for up to two years. Mounjaro is recommended by NICE (TA1026, December 2024) and is being rolled out on the NHS in phases, with GP practices able to prescribe under the programme since April 2026. Whatever the route, these are prescription-only medicines that can be supplied lawfully only by a regulated UK pharmacy against a valid prescription.
What this article cannot tell you
It cannot tell you which one to ask for. Format preference is only one input; a prescriber weighs your medical history, other conditions, other medicines, how you tolerate the early weeks, and whether a medicine is licensed for your situation at all. NICE advises reassessing Mounjaro if less than 5% of starting weight is lost six months after reaching the highest tolerated dose — a reminder that none of these is a one-way commitment.
And where the licensed information is silent — what to do about a particular missed dose, for instance — the right answer is the patient information leaflet in the pack and a word with your pharmacist, not a guess from a website. For a broader side-by-side, see our comparison page or the article on GLP-1 medications compared.
Frequently asked questions
Are GLP-1 tablets as effective as the injections?
Not identically, and because the trials were separate they cannot be read as a head-to-head. In its own trial the Wegovy pill averaged about 13.6% of body weight at 25 mg over 64 weeks — about 16.6% among people who took it consistently — and Foundayo averaged about 12.4% at 17.2 mg over 72 weeks. The weekly injections averaged about 15% for Wegovy over 68 weeks and around 21–22% for Mounjaro on its higher doses over 72 weeks. Individual results vary widely, and an average is not a prediction for any one person.
Do I really have to fast before taking the Wegovy pill?
Yes — the routine is part of how the medicine works, not a suggestion. The tablet is swallowed whole with a small sip of plain water (no more than about 120 ml), first thing in the morning on an empty stomach after an overnight fast of at least 8 hours, and you then wait at least 30 minutes before eating, drinking anything else, or taking other tablets. Each tablet includes an absorption enhancer called SNAC to help the semaglutide survive the stomach, which is why the timing matters.
Can you take Foundayo with food?
Yes. Foundayo is a small-molecule drug that is absorbed like an ordinary tablet whatever you have eaten, so it is one tablet a day at any time of day, with or without food, with no water limit and no waiting before breakfast. Swallow it whole — do not break, crush or chew it — and keep it in its original blister, as it is light-sensitive. It does not need a fridge.
How long does it take to reach the full dose on a tablet compared with an injection?
The Wegovy pill takes about three months to reach its 25 mg maintenance dose, with at least a month each at 1.5 mg, 4 mg and 9 mg first. Foundayo reaches 5.5 mg — the first dose you may stay on — after two 30-day steps, and the earliest anyone can reach the maximum 17.2 mg is month 6. The Wegovy injection reaches its usual 2.4 mg maintenance dose from around week 17. Mounjaro reaches its lowest maintenance dose, 5 mg, after the four-week starter month, with at least four further four-week steps to get to 15 mg.
What happens if I miss a dose?
For Foundayo, the UK information says to take it when you remember that day, and never to take two in one day. For the other three medicines, what to do about a specific missed dose is set out in the patient information leaflet inside the pack — read that and ask your pharmacist if you are unsure. Do not guess, and do not double up without checking.
Can I switch from an injection to a tablet?
People stepping down from Mounjaro or Wegovy injections are one of the groups Foundayo is described as suiting: in a 52-week trial it kept most of the weight off after switching. But a switch is a prescribing decision, not a swap you make yourself — the dose ladders are not interchangeable, and you would begin the tablet at its own starter dose. Raise it with your prescriber before changing anything.
Are the GLP-1 tablets available on the NHS?
Not at the moment. The Wegovy pill was approved by the MHRA on 11 June 2026 and is available on private prescription only; NHS funding would need a separate NICE appraisal. Foundayo was authorised on 10 August 2026 and is also private-only, with a NICE appraisal (ID6516) in progress and guidance provisionally expected on 18 November 2026. Of the injections, Wegovy is available on the NHS in England only through specialist weight-management services (NICE TA875), and Mounjaro through the phased rollout under NICE TA1026.